CU20130012A7 - Conjugado de factor estimulante de colonia de granulocito (g-csf)con polietileno glicol - Google Patents

Conjugado de factor estimulante de colonia de granulocito (g-csf)con polietileno glicol

Info

Publication number
CU20130012A7
CU20130012A7 CUP2013000012A CU20130012A CU20130012A7 CU 20130012 A7 CU20130012 A7 CU 20130012A7 CU P2013000012 A CUP2013000012 A CU P2013000012A CU 20130012 A CU20130012 A CU 20130012A CU 20130012 A7 CU20130012 A7 CU 20130012A7
Authority
CU
Cuba
Prior art keywords
csf
conjugate
stimulating factor
granulocit
colonia
Prior art date
Application number
CUP2013000012A
Other languages
English (en)
Other versions
CU24139B1 (es
Inventor
Tatyana Veniaminovna Chernovskaya
Dmitriy Valentinovich Morozov
Lev Alexandrovich Denisov
Elena Georgievna Rudenko
Angelina Vsevolodovna Klenova
Original Assignee
Biocad Cjsc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45567857&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20130012(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biocad Cjsc filed Critical Biocad Cjsc
Publication of CU20130012A7 publication Critical patent/CU20130012A7/es
Publication of CU24139B1 publication Critical patent/CU24139B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona con productos farmacéuticos y el sector de la medicina, específicamente,con un nuevo conjugado fisiológicamente activo de factor estimulante de colonia de granulocito ( G-CSF) con la fórmula general: donde: n-es un número entero de 681 a 1 000; m-entero>4; NaH-G-CSF-es un polipéptido natural o recombinante, teniendo actividad de G-CSF. La invención también está relacionada con medicamentos conteniendo el conjugado de fórmula (1), composiciones farmacéuticas con el factor estimulante de colonia de granulocito como un ingrediente activo, y un contenedor que contiene la composición farmacéutica, útiles para prevenir y/o tratar la neutropenia.
CU20130012A 2010-08-13 2011-07-19 Conjugado de factor estimulante de colonia de granulocito (g-csf)con polietileno glicol CU24139B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2010133875/10A RU2446173C1 (ru) 2010-08-13 2010-08-13 Новый функционально активный, высокоочищенный стабильный конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем с пролонгированным биологическим действием, пригодный для медицинского применения, и иммунобиологическое средство на его основе
PCT/RU2011/000532 WO2012021088A1 (en) 2010-08-13 2011-07-19 A novel conjugate of granulocyte colony-stimulating factor (g-csf) with polyethylene glycol

Publications (2)

Publication Number Publication Date
CU20130012A7 true CU20130012A7 (es) 2013-04-19
CU24139B1 CU24139B1 (es) 2015-12-23

Family

ID=45567857

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20130012A CU24139B1 (es) 2010-08-13 2011-07-19 Conjugado de factor estimulante de colonia de granulocito (g-csf)con polietileno glicol

Country Status (18)

Country Link
KR (1) KR101549457B1 (es)
CN (1) CN103140499B (es)
CL (1) CL2013000400A1 (es)
CO (1) CO6670557A2 (es)
CR (1) CR20130020A (es)
CU (1) CU24139B1 (es)
DO (1) DOP2013000003A (es)
EA (1) EA019043B1 (es)
EC (1) ECSP13012399A (es)
MA (1) MA34525B1 (es)
MY (1) MY160732A (es)
NI (1) NI201300007A (es)
PE (1) PE20131085A1 (es)
PH (1) PH12012502426A1 (es)
RS (1) RS20130094A1 (es)
RU (1) RU2446173C1 (es)
SG (1) SG187572A1 (es)
WO (1) WO2012021088A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012110057A1 (en) 2011-02-15 2012-08-23 Chemisches Institut Schaefer Ag Cefuroxime safety kit
EP2858636B1 (en) 2012-06-07 2018-09-05 Childrens Hospital Los Angeles Methods for treating neutropenia using retinoid agonists
CN103908427B (zh) * 2013-01-05 2014-12-17 石药集团百克(山东)生物制药有限公司 一种聚乙二醇修饰的rhG-CSF注射液及其制备方法
RU2535002C2 (ru) * 2013-04-04 2014-12-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Средство коррекции отдаленных последствий нарушений сперматогенеза, вызванных цитостатическим воздействием
KR20160113302A (ko) 2014-02-18 2016-09-28 칠드런＇스 하스피틀 로스 앤젤레스 호중구감소증을 치료하기 위한 조성물 및 방법
ES3002087T3 (en) 2014-07-14 2025-03-06 Gennova Biopharmaceuticals Ltd A novel process for purification of rhu-gcsf
IL247369B (en) * 2016-08-18 2018-08-30 B G Negev Tech And Applications Ltd Polypeptides derived from CSF-m and their uses
KR102020995B1 (ko) * 2017-10-30 2019-09-16 한국코러스 주식회사 콜로니자극인자와 폴리올이 접합된 접합물을 고수율로 제조하는 방법
NZ791835A (en) * 2020-03-17 2025-10-31 Drugrecure Aps Liquid formulation of gm-csf for inhalation
JP2023518412A (ja) * 2020-03-20 2023-05-01 アムジェン インコーポレイテッド 酸性プロテアーゼを使用するペグフィルグラスチムの遊離ｎ末端の決定

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2989002B2 (ja) * 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
KR20040083268A (ko) * 2003-03-21 2004-10-01 한미약품 주식회사 안정성이 증가된 인간 과립구 콜로니 자극인자 융합체 및이의 제조방법
RU2278870C2 (ru) * 2004-08-30 2006-06-27 Закрытое Акционерное Общество "Биокад" Способ получения, выделения, очистки и стабилизации рекомбинантного гранулоцитарного колониестимулирующего фактора человека, пригодного для медицинского применения, и иммунобиологическое средство на его основе
MX2008009125A (es) * 2006-01-18 2008-10-23 Qps Llc Composiciones farmaceuticas con estabilidad mejorada.
EP2044097A4 (en) * 2006-06-23 2010-10-06 Quintessence Biosciences Inc Modified ribonucleases

Also Published As

Publication number Publication date
CO6670557A2 (es) 2013-05-15
CU24139B1 (es) 2015-12-23
KR101549457B1 (ko) 2015-09-02
CN103140499A (zh) 2013-06-05
RU2446173C1 (ru) 2012-03-27
SG187572A1 (en) 2013-03-28
DOP2013000003A (es) 2013-07-31
CL2013000400A1 (es) 2013-07-26
EA201101035A1 (ru) 2012-02-28
PE20131085A1 (es) 2013-10-10
PH12012502426A1 (en) 2021-06-02
MY160732A (en) 2017-03-15
CN103140499B (zh) 2014-12-17
RS20130094A1 (sr) 2013-08-30
WO2012021088A1 (en) 2012-02-16
EA019043B1 (ru) 2013-12-30
NI201300007A (es) 2014-05-26
CR20130020A (es) 2013-02-20
MA34525B1 (fr) 2013-09-02
KR20130043167A (ko) 2013-04-29
ECSP13012399A (es) 2013-05-31

Similar Documents

Publication Publication Date Title
CU20130012A7 (es) Conjugado de factor estimulante de colonia de granulocito (g-csf)con polietileno glicol
BR112013003045A2 (pt) composto e composição farmacêutica e respectivos usos, recipiente estéril e método para preparar composição farmacêutica para administração
UA103221C2 (uk) Стабільний склад рекомбінантного альбуміну людини-гранулоцитарного колонієстимулюючого фактора людини
EA201690102A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
UA109010C2 (en) Morpholino pyrividines and their use in therapy
EA201390409A1 (ru) Составы с низкой дозой панкрелипазы и кишечно-растворимым покрытием
CU23734A1 (es) Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
BR112015012366A8 (pt) antagonistas de cxcr7, uso dos mesmos, composição farmacêutica, bem como métodos para detectar níveis elevados de cxcr7 em uma amostra e para imagear um tumor, órgão, ou tecido
UA115139C2 (uk) Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
MX2011008634A (es) Derivados de aminotetralina composiciones farmaceuticas que los contienen y su uso en terapia.
NZ605888A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain
BR112013031268A2 (pt) "polipeptídeos análogos de pramlintida, uso dos mesmos, composição farmacêutica compreendendo os referidos polipeptídeos e método de preparação da referida composição".
PH12013500152A1 (en) New aminopyrazoloquinazolines
BR112012026596A2 (pt) método para preparar composições farmacêuticas pretendidas para administração oral compreendendo um ou mais ingredientes ativos e as composições que compreendem as mesmas
BR112015025804A2 (pt) derivados de glutarimida, uso dos mesmos, composição farmacêutica com base neles e métodos para a produção de derivados de glutarimida
MX2022006519A (es) Medicamento conjugado con polietilenglicol, metodo de preparacion del mismo y uso del mismo.
MX2015004362A (es) Derivados de ketamina.
PH12014502619A1 (en) Novel dosage and formulation
EA201300857A1 (ru) Пиразолы в качестве антагонистов crth2
BR112013006651A2 (pt) composição e cocristal de aprepitante l-prolina
CY1117596T1 (el) Φαρμακευτικeς συνθeσεις αερολyματος φορμοτερολης και διπροπιονικης βεκλομεθαζονης
MX2013003545A (es) Peptidos del veneno de escorpion rhopalorus junceus y composicion farmaceutica.
CY1115600T1 (el) Πιπεραζινες ως ανθελονοσιακοι παραγοντες
NZ599901A (en) Improved medicinal aerosol formulations